SEARCH

SEARCH BY CITATION

References

  • 1
    Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31:10051013.
  • 2
    Neuberger J. Primary biliary cirrhosis. Lancet 1997; 350:875879.
  • 3
    Heathcote J. Update on primary biliary cirrhosis. Can J Gastroenterol 2000; 14:4348.
  • 4
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324:15481554.
  • 5
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884890.
  • 6
    Leuschner M, Dietrich CF, You T, Seidl C, Raedle J, Herrmann G, Ackermann H, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000; 46:121126.
  • 7
    Pasha TM, Lindor KD. Diagnosis and therapy of cholestatic liver disease. Med Clin North Am 1996; 80:9951019.
  • 8
    Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10:420429.
  • 9
    Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117:918925.
  • 10
    Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, Reshef R, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115:835840.
  • 11
    Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331:836841.
  • 12
    Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982; 122:8695.
  • 13
    Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995; 23:137142.
  • 14
    Möllmann HW, Barth J, Hochhaus G, Möllmann AC, Derendorf H, Tromm A. Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. In: MöllmannHW, MayB, eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996:4260.
  • 15
    Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31:318323.
  • 16
    George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21:120128.
  • 17
    Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 1999; 37:399431.
  • 18
    Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16:707714.
  • 19
    Rowland M, Tozer T. Clinical Pharmacokinetics. Concepts and Applications. Baltimore: Williams & Wilkins, 1995:117130.
  • 20
    Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992; 30:S45S50.
  • 21
    Möllmann H, Hochhaus G, Tromm A, Froehlich P, Möllmann A, Krieg M, Weisser H, et al. Pharmacokinetics and pharmacodynamics of budesonide-ph-modified release capsules. In: MöllmannH, MayB, eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996:107120.
  • 22
    Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89:221231.
  • 23
    Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89:273293.
  • 24
    Pihusch R, Rank A, Gohring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37:548555.
  • 25
    McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21:4269.
  • 26
    Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995; 29:370391.
  • 27
    Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41:235253.
  • 28
    Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40:723751.
  • 29
    Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide Enema Study Group. Gastroenterology 1998; 115:525532.
  • 30
    Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103:414421.
  • 31
    Nana A, Youngchaiyud P, Charoenratanakul S, Boe J, Lofdahl CG, Selroos O, Stahl E. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma 1998; 35:647655.
  • 32
    Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:23332337.
    Direct Link: